ArriVent BioPharma, Inc. Common Stock
NasdaqGM AVBP
ArriVent BioPharma, Inc. Common Stock Free Cash Flow Yield on January 14, 2025
-
ArriVent BioPharma, Inc. Common Stock 52-week high Free Cash Flow Yield is NA on January 14, 2025, which is NA below the current Free Cash Flow Yield.
-
ArriVent BioPharma, Inc. Common Stock 52-week low Free Cash Flow Yield is NA on January 14, 2025, which is NA below the current Free Cash Flow Yield.
-
ArriVent BioPharma, Inc. Common Stock average Free Cash Flow Yield for the last 52 weeks is NA.
| Date | Free Cash Flow Yield | Market Value Added (MVA) | Price to Book Ratio (P/B) | Price to Earnings Ratio (P/E) |
|---|
| CEO | Dr. Zhengbin Yao Ph.D. |
| IPO Date | Jan. 26, 2024 |
| Location | United States |
| Headquarters | 18 Campus Boulevard |
| Employees | 40 |
| Sector | Health Care |
| Industries | |
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email